Yesterday, a Food and Drug Administration advisory panel recommended that the agency approve a new drug, flibanserin, which would be marketed under the brand name Addyi. In headlines and in news reports, you see references to the drug as a “pink Viagra” or “Viagra for women.” Yet the drug works on the brain, not the genitals, and critics say that its side effects may not be worth its proven benefits. The FDA has already rejected the drug twice. [More]
